Year: 2024

Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 52 Investigative Sites Now Initiated Cash Runway Through End of 2027 CHAPEL HILL, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced financial results for the third quarter of 2024 and provided a corporate update. “The third quarter showcased strong execution across our company,” said Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics. “We expanded our pivotal Phase 3 LEVEL study by initiating...

TORONTO, Nov. 13, 2024 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and nine months ended September 30, 2024. Summary of Financial Results & Recent Progress:Company continues to execute against Transformation PlanCash used in operations for the first nine months of 2024 of $7.3 million, down 40% year-over-yearTotal revenue for the third quarter of $15.0 million, down 15% year-over-year, and below third quarter estimate of at “least $17.0 million”.Third quarter operating expenses declined 10% year-over-year; limiting GAAP operating loss to 6% year-over-year, despite 15% revenue decline Third quarter Adjusted EBITDA loss of $5.9 million, compared to $4.6 million last yearOn July 29,...

SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) — Wag! Group Co. (the “Company” or “Wag!”; Nasdaq: PET), which strives to be the number one platform to solve the service, product, and wellness needs of the modern U.S. pet household, today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights:Revenues decreased 39% to $13.2 million, compared to $21.8 million in the third quarter of 2023 – comprised of $5.4 million of Services revenue, $6.5 million of Wellness revenue, and $1.3 million of Pet Food & Treats revenue. Net loss was $6.3 million, compared to $2.2 million in the third quarter of 2023. Adjusted EBITDA loss was $1.9 million, compared to positive Adjusted EBITDA of $1.0 million in the third quarter of 2023.“Our third quarter results were impacted by a highly dynamic...

GREENWICH, Conn., Nov. 13, 2024 (GLOBE NEWSWIRE) — QXO, Inc. (Nasdaq: QXO) today announced its financial results for the third quarter 2024. The company reported a loss of $0.01 per basic and diluted share attributable to common shareholders.THIRD QUARTER 2024 SUMMARY RESULTS                                             Three Months Ended         Nine Months Ended        September 30,   September 30,   Percent   September 30,   September 30,   Percent(in thousands)   2024        2023      Change   2024    2023    ChangeRevenue:                                          Software product, net $ 3,028     $ 2,850     6.2 %   $ 10,284     $ 9,471     8.6 %Service and other, net   10,127       10,573     (4.2 )%     31,846       30,337     5.0 %Total revenue, net $ 13,155     $ 13,423     (2.0 )%   $ 42,130     $ 39,808     5.8 %                                           Net...

– Reprioritized resources to reduce costs and enhance focus on Nana-val’s development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) – – On track to report data from expansion phase of the Phase 2 NAVAL-1 clinical trial of Nana-val in the first half of 2025 – – Determined recommended Phase 2 dose of Nana-val in patients with advanced EBV-positive solid tumors – SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today reported financial results for the third quarter of 2024 and provided a business update. “Last quarter, based on productive feedback from FDA, we announced a sharpened...

Last Patient Enrolled for Planned Unblinded Interim Analysis in Ongoing SHIELD II Phase 3 Trial of D-PLEX100  Unblinded Interim Analysis Outcome Expected Later this Quarter SHIELD II Enrollment Completion Expected in December 2024 with Top-Line Results Anticipated in First Quarter of 2025 Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Nov. 13, 2024 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three and nine months ended September 30, 2024. Recent Corporate Highlights:Over 540 patients have been enrolled to date in the ongoing SHIELD II Phase 3 trial of D-PLEX100 for the prevention of abdominal colorectal surgical site infections (SSIs).Recently...

Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort 2 data expected in 1H25 Updated interim data from Cohort 1 FTD-GRN showed PBFT02 was generally well-tolerated and elevated CSF progranulin levels for up to 12 months following treatment Highlighted robust preclinical data supporting PBFT02 as a potential best-in-class progranulin-raising therapy in an oral presentation at ESGCT Execution backed by strong balance sheet, with cash runway to the end of Q2 2026 PHILADELPHIA, Nov. 13, 2024 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the third quarter ended September 30, 2024 and...

Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Candidate nominations for IL-18 and IL-12 programs expected in Q4 2024, and IND submission for Mural’s IL-18 program planned for Q4 2025 Mural reiterates guidance on projected cash runway into Q4 2025 WALTHAM, Mass. and DUBLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) — Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced financial results for the third quarter of 2024 and provided an update on pipeline progress. “Mural launched as a stand-alone...

25% Year-over-Year Top Line Revenue Growth; 53% increase in Adjusted EBITDA to $2.3 Million; On Track for Best Year Ever LOUISVILLE, Ky., Nov. 13, 2024 (GLOBE NEWSWIRE) — Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX), a leading provider of digital signage and media solutions, today announced its financial results for the fiscal third quarter ended September 30, 2024. Highlights:Record third quarter revenue of $14.4 million, up 25% from $11.6 million in the prior-year period Gross profit of $6.6 million for the three months ended September 30, 2024 versus $5.3 million in the third quarter of fiscal 2023, an increase of 25% Net Income improved by $1.9 million during third quarter, to breakeven, as compared to third quarter prior year Adjusted EBITDA* of $2.3 million for the third quarter...